Biomedical Diagnostics Institute Purchases Biacore A100 Label-free Protein Interaction Analysis System
News Oct 07, 2008
The Biomedical Diagnostics Institute (BDI) based at Dublin City University (DCU) announced that it has invested in Biacore™ A100 label-free protein interaction analysis system.
The BDI is focused on the development of point of care diagnostics. Biacore A100 will be officially launched by the BDI on 7th October 2008.
The investment in the instrument was made possible following a significant award from Science Foundation Ireland (SFI). The BDI becomes the first academic research institute in Europe to own Biacore A100.
“Key characteristics of binding molecules, such as antibody fragments, empirically alter the specificity, sensitivity and potential application of new analytical platforms such as the next generation biomedical point-of-care biochips being developed at the BDI. The generation of data by Biacore A100, such as thermodynamic stability and binding kinetics, is of critical importance for the incorporation of antibody fragments onto the BDI’s novel biochip platforms,” commented Prof. Richard O’Kennedy, DCU.
Biacore A100 was thoroughly evaluated by BDI scientists prior to being installed at DCU. The high quality and high content data generated by the instrument, parallel sample analysis and high productivity along with the ability to analyze ~2000 interactions in 24 hours were key factors in the decision to purchase the instrument.
In addition, the biosensor utilizes sensor chips amenable to a variety of immobilization chemistries, enabling it to be used for a wide range of applications.
The BDI is an Academic-Industry-Clinical partnership founded in October 2005 at DCU to develop next-generation biomedical diagnostic devices. The devices are designed for point of care as well as self-test, home use. The multidisciplinary research institute brings together leading researchers from academic, corporate and clinical backgrounds.
Automated Robotic Device Enables Faster Blood TestingNews
Rutgers researchers have created an automated blood drawing and testing device that provides rapid results, potentially improving the workflow in hospitals and other health-related institutions to allow health care practitioners to spend more time treating patients.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE